vTv Therapeutics Q2 net loss $6.0M; Phase 3 T1D trial randomized

vTv Therapeutics Inc.

Net loss attributable to vTv shareholders of $6.0M ($0.92/share) vs $5.2M ($0.81/share) in Q2 2024.
Cash and cash equivalents $25.9M at June 30, 2025, down from $36.7M at December 31, 2024.
First patient randomized in Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes; topline data expected H2 2026.
Appointed Michael Tung, MD, MBA as CFO in May 2025.
USPTO allowed patent claims for crystalline salt form of cadisegliatin with term through 2041.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.